Skip to content667, L.P. — SEATTLE GENETICS INC /WA insider: 639 transactions · InsiderLens667, L.P.
- Director at SYNTA PHARMACEUTICALS CORP · on record since Jun 20, 2023
- Former 10% Owner at Neurogene Inc. · on record since Dec 20, 2023
- Former 10% Owner at SEATTLE GENETICS INC /WA · on record since Dec 18, 2023
- Director at vTv Therapeutics Inc. · on record since Mar 7, 2024
- Director at Immunocore Holdings plc · on record since May 29, 2024
- Director at BICYCLE THERAPEUTICS PLC · on record since May 29, 2024
- 10% owner at BICYCLE THERAPEUTICS PLC · on record since May 29, 2024
- Director at Kymera Therapeutics, Inc. · on record since Apr 1, 2024
- Director at TScan Therapeutics, Inc. · on record since May 22, 2026
- Former 10% owner and director at IGM Biosciences, Inc. · on record since Aug 18, 2025
- 10% owner at Kymera Therapeutics, Inc. · on record since Dec 11, 2025
- Director at INCYTE CORP · on record since Apr 2, 2026
- 10% owner at INCYTE CORP · on record since Apr 2, 2026
- Director at Replimune Group, Inc. · on record since Apr 7, 2026
- 10% owner at Replimune Group, Inc. · on record since Apr 7, 2026
- Director at BeOne Medicines Ltd. · on record since May 27, 2026
- Director at Prelude Therapeutics Inc · on record since Apr 22, 2026
- 10% owner at Prelude Therapeutics Inc · on record since Apr 22, 2026
- Director at GENOMIC HEALTH INC · on record since Jul 31, 2012
- Director at XOMA LTD /DE/ · on record since Jul 23, 2012
- Director at TRIMERIS INC · on record since Jul 13, 2012
- 10% owner at XOMA LTD /DE/ · on record since Oct 31, 2012
- 10% owner at GENOMIC HEALTH INC · on record since Nov 23, 2012
- Director at ACADIA PHARMACEUTICALS INC · on record since Jan 23, 2013
- 10% owner at ACADIA PHARMACEUTICALS INC · on record since Jan 23, 2013
- Director at SEATTLE GENETICS INC /WA · on record since May 21, 2013
- 10% owner at SEATTLE GENETICS INC /WA · on record since May 21, 2013
- 10% owner at TRIMERIS INC · on record since Jun 10, 2013
- 10% owner at BIOCRYST PHARMACEUTICALS INC · on record since Aug 2, 2013
- Director at IDERA PHARMACEUTICALS, INC. · on record since Mar 19, 2014
- Director at Kiniksa Pharmaceuticals International, plc · on record since Jun 2, 2026
- Director at Denali Therapeutics Inc. · on record since Jun 5, 2026
- 10% owner at Mirati Therapeutics, Inc. · on record since Feb 2, 2015
- Director at ALEXION PHARMACEUTICALS INC · on record since Jun 30, 2015
- Former 10% owner and Director at TRIMERIS INC · on record since Jun 23, 2015
- Former 10% owner at XOMA LTD /DE/ · on record since Jul 23, 2015
- 10% owner at Neurogene Inc. · on record since Aug 10, 2015
- 10% owner at BeOne Medicines Ltd. · on record since Feb 9, 2016
- Director at Neurogene Inc. · on record since May 9, 2017
- 10% owner at IDERA PHARMACEUTICALS, INC. · on record since Mar 15, 2018
- 10% owner at Kiniksa Pharmaceuticals International, plc · on record since May 31, 2018
- Director at Kodiak Sciences Inc. · on record since Oct 11, 2018
- 10% owner at Kodiak Sciences Inc. · on record since Oct 11, 2018
- Director at IGM Biosciences, Inc. · on record since Sep 20, 2019
- 10% owner at IGM Biosciences, Inc. · on record since Sep 20, 2019
- Director at SMI PRODUCTS INC · on record since Dec 20, 2019
- 10% owner at SMI PRODUCTS INC · on record since Oct 15, 2019
- Director at Zymeworks Inc. · on record since Mar 16, 2020
- Director at Spyre Therapeutics, Inc. · on record since Feb 25, 2021
- Director at Talis Biomedical Corp · on record since Feb 19, 2021
- 10% owner at Talis Biomedical Corp · on record since Feb 19, 2021
- Director at DBV Technologies S.A. · on record since Jan 11, 2021
- 10% owner at DBV Technologies S.A. · on record since Jan 11, 2021
- 10% owner at TScan Therapeutics, Inc. · on record since Jul 15, 2021
Insider trading activity of 667, L.P.
- Transactions on record
- 639
- since Feb 11, 2013
- Open-market buys
- 308
- $837M
- Open-market sells
- 117
- $70.8M
- Companies traded
- 19
- last filing Jul 2, 2025
Figures computed from official regulatory filings — methodology.
Companies where 667, L.P. has traded
- IGM Biosciences, Inc.12 tx · $65M · Jul 2, 2025
- TScan Therapeutics, Inc.21 tx · $167.9M · Jul 2, 2025
- Kodiak Sciences Inc.14 tx · $10M · Jul 2, 2025
- INCYTE CORP79 tx · $211.5M · Apr 2, 2025
- Immunocore Holdings plc6 tx · $24M · Mar 19, 2025
- Kymera Therapeutics, Inc.3 tx · $105.7M · Aug 22, 2024
- vTv Therapeutics Inc.8 tx · Jun 27, 2024
- BICYCLE THERAPEUTICS PLC4 tx · Jun 20, 2024
- SEATTLE GENETICS INC /WA190 tx · $10.6B · Dec 18, 2023
Track record of 667, L.P.
Statistical track record
Free- Open-market buys
- 314
- Last buy
- Mar 17, 2025
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of 667, L.P.
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
30 tx · $7.5M · Dec 14, 2023
14159 capital (GP), LLCIDERA PHARMACEUTICALS, INC. +4
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jul 2, 2025 | AwardD | 67,000 | 0.00 USD | $0 | SEC |
| Jul 2, 2025 | AwardD | 40,000 | 0.00 USD | $0 | SEC |
| Jul 2, 2025 | AwardD | 40,000 | 0.00 USD | $0 | SEC |
| Jul 2, 2025 | Award | 953 | 0.00 USD | $0 | SEC |
| Jul 2, 2025 | Award | 953 | 0.00 USD | $0 | SEC |
| Jul 2, 2025 | AwardD | 67,000 | 0.00 USD | $0 | SEC |
| Apr 2, 2025 | Award | 487 | 0.00 USD | $0 | SEC |
| Apr 2, 2025 | Award | 953 | 0.00 USD | $0 | SEC |
| Apr 2, 2025 | Award | 953 | 0.00 USD | $0 | SEC |
| Apr 2, 2025 | Award | 487 | 0.00 USD | $0 | SEC |
| Mar 19, 2025 | Buy | 92,349 | 29.56 USD | $2.7M | SEC |
| Mar 19, 2025 | Buy | 60,110 | 29.74 USD | $1.8M | SEC |
| Mar 19, 2025 | SellD | 0 | 10,533,376.12 USD | $0 | SEC |
| Mar 19, 2025 | Buy | 8,589 | 29.56 USD | $253.9K | SEC |
| Mar 19, 2025 | Buy | 646,290 | 29.74 USD | $19.2M | SEC |
| Mar 19, 2025 | SellD | 0 | 113,252,773.88 USD | $0 | SEC |
| Aug 22, 2024 | BuyD | 2,246,587 | 40.75 USD | $91.5M | SEC |
| Aug 22, 2024 | Buy | 1 | 46.41 USD | $46.4 | SEC |
| Aug 22, 2024 | BuyD | 347,572 | 40.75 USD | $14.2M | SEC |
| Jul 2, 2024 | AwardD | 40,000 | 0.00 USD | $0 | SEC |
| Jul 2, 2024 | AwardD | 40,000 | 0.00 USD | $0 | SEC |
| Jun 27, 2024 | AwardD | 6,000 | 0.00 USD | $0 | SEC |
| Jun 27, 2024 | AwardD | 983 | 0.00 USD | $0 | SEC |
| Jun 27, 2024 | AwardD | 6,000 | 0.00 USD | $0 | SEC |
| Jun 27, 2024 | AwardD | 983 | 0.00 USD | $0 | SEC |